Table 1.
Characteristics of patients with Crohn’s disease hospitalized for intra-abdominal abscess.
| Total (n = 99) | PO Antibiotics (n = 74) | IV Antibiotics (n = 25) | P | |
|---|---|---|---|---|
| Demographics | ||||
| Age, median (Q1-Q3) | 27 (21-38) | 28 (18) | 22 (8) | <.01 |
| Female Sex, n (%) | 40 (40) | 33 (45) | 7 (28) | .14 |
| Median duration of Crohn’s Disease, years (Q1-Q3) | 4 (0-13) | 2 (15) | 4 (9) | .69 |
| Current Smoker, n (%) | 16 (16) | 5 (7) | 1 (4) | .65 |
| Medical History | ||||
| Previous history of CD-related surgery, n (%) | 21 (21) | 17 (23) | 4 (16) | .46 |
| History of penetrating Crohn’s Disease, n (%) | 22 (22) | 13 (18) | 9 (36) | .06 |
| History of perianal Crohn’s Disease, n (%) | 18 (18) | 14 (19) | 4 (16) | .74 |
| Montreal classification of active disease at abscess diagnosis, n (%) | ||||
| L1 | 35 (35) | 31 (41) | 4 (16) | .02 |
| L2 | 5 (5) | 5 (7) | 0 (0) | .18 |
| L3 | 59 (60) | 38 (51) | 21 (84) | <.01 |
| Medications prior to abscess diagnosis, n (%) | ||||
| Steroids | 45 (46) | 31 (42) | 14 (56) | .22 |
| 5-aminosalicylic acid | 19 (19) | 12 (16) | 7 (28) | .19 |
| Immunomodulators | 18 (18) | 12 (16) | 6 (24) | .38 |
| Anti-Tumor Necrosis Factor (TNF) | 20 (20) | 13 (17) | 7 (28) | .23 |
| Combination Anti-TNF/immunomodulator | 5 (5) | 3 (4) | 2 (8) | .44 |
| Anti-Integrin | 3 (3) | 3 (4) | 0 (0) | .31 |
| Anti-Interleukin 12/23 | 5 (5) | 2 (3) | 3 (12) | .07 |
| Abscess Characteristics | ||||
| Abscess Size, n (%) | .59 | |||
| 0-3 cm | 34 (37) | 24 (34) | 10 (44) | |
| 3-6 cm | 45 (48) | 36 (51) | 9 (39) | |
| >6 cm | 14 (15) | 10 (14) | 4 (17) | |
| Abscess Location, n (%) | .47 | |||
| Ileum | 67 (68) | 49 (66) | 18 (72) | |
| Other small bowel | 13 (13) | 10 (14) | 3 (12) | |
| Large Bowel | 11 (11) | 7 (10) | 4 (16) | |
| Ileum and large bowel | 7 (7) | 7 (10) | 0 (0) |